Avila Villanueva, MarinaMarcos Dolado, AlbertoFernández Blázquez, Miguel Ángel2026-01-202026-01-202023-06Ávila-Villanueva M, Dolado AM, Fernández-Blázquez M. How to Prevent and/or Revert Alzheimer’s Disease Continuum During Preclinical Phases. Journal of Alzheimer’s Disease Reports. 2023;7(1):505-512. doi:10.3233/ADR22010010.3233/ADR-220100https://hdl.handle.net/20.500.14352/130631This work has been done during a Margarita Salas contract founded by Next Generation EUThe development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of “precision medicine” in healthcare systems worldwide.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/journal articlehttps://doi.org/10.3233/ADR220100open accessAlzheimer’s disease continuumModifable risk factorsPrecision medicineSleep disturbancesCiencias Biomédicas32 Ciencias Médicas